Last Updated : October 4, 2024
Details
Generic Name:
pembrolizumab
Project Status:
Pending
Therapeutic Area:
Advanced or recurrent endometrial carcinoma
Manufacturer:
Merck Canada Inc.
Call for patient/clinician input open:
Brand Name:
Keytruda
Project Line:
Reimbursement Review
Project Number:
PC0383-000
Call for patient/clinician input closed:
Tumour Type:
Genitourinary
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Pembrolizumab (Keytruda) in combination with chemotherapy for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma (EC), and then continued as monotherapy.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Pembrolizumab (Keytruda) in combination with chemotherapy for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma (EC), and then continued as monotherapy.
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : October 4, 2024